These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 7524598

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture.
    Mohrmann M, Ansorge S, Schmich U, Schönfeld B, Brandis M.
    Pediatr Nephrol; 1994 Apr; 8(2):157-63. PubMed ID: 7517170
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.
    Brock N, Pohl J.
    IARC Sci Publ; 1986 Apr; (78):269-79. PubMed ID: 3108156
    [Abstract] [Full Text] [Related]

  • 6. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
    Kurowski V, Wagner T.
    Cancer Chemother Pharmacol; 1997 Apr; 39(5):431-9. PubMed ID: 9054957
    [Abstract] [Full Text] [Related]

  • 7. Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds.
    Brock N, Pohl J, Stekar J.
    J Cancer Res Clin Oncol; 1981 Apr; 100(3):311-20. PubMed ID: 6792207
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of sodium-dependent transport systems in LLC-PK1 cells by metabolites of ifosfamide.
    Mohrmann M, Pauli A, Ritzer M, Schönfeld B, Seifert B, Brandis M.
    Ren Physiol Biochem; 1992 Apr; 15(6):289-301. PubMed ID: 1282722
    [Abstract] [Full Text] [Related]

  • 9. Comparative toxicity of ifosfamide metabolites and protective effect of mesna and amifostine in cultured renal tubule cells.
    Zaki EL, Springate JE, Taub M.
    Toxicol In Vitro; 2003 Aug; 17(4):397-402. PubMed ID: 12849722
    [Abstract] [Full Text] [Related]

  • 10. Effect of ifosfamide metabolites on sodium-dependent phosphate transport in a model of proximal tubular cells (LLC-PK1) in culture.
    Mohrmann M, Pauli A, Walkenhorst H, Schönfeld B, Brandis M.
    Ren Physiol Biochem; 1993 Aug; 16(6):285-98. PubMed ID: 7506438
    [Abstract] [Full Text] [Related]

  • 11. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna).
    Habs MR, Schmähl D.
    Cancer; 1983 Feb 15; 51(4):606-9. PubMed ID: 6401591
    [Abstract] [Full Text] [Related]

  • 12. Reduction of dimesna to mesna by the isolated perfused rat liver.
    Goren MP, Hsu LC, Li JT.
    Cancer Res; 1998 Oct 01; 58(19):4358-62. PubMed ID: 9766664
    [Abstract] [Full Text] [Related]

  • 13. Antitumor activity of 2-mercaptoethanesulfonate (mesna) in vitro. Its potential use in the treatment of superficial bladder cancer.
    Blomgren H, Hallström M, Hillgren H.
    Anticancer Res; 1991 Oct 01; 11(2):773-6. PubMed ID: 1905905
    [Abstract] [Full Text] [Related]

  • 14. Enzymatic and non-enzymatic mechanisms of dimesna metabolism.
    Cutler MJ, Velenosi TJ, Bodalia A, House AA, Urquhart BL, Freeman DJ.
    Amino Acids; 2015 Mar 01; 47(3):511-23. PubMed ID: 25488427
    [Abstract] [Full Text] [Related]

  • 15. Ifosfamide induced depletion of glutathione in human peripheral blood lymphocytes and protection by mesna.
    Meier T, Allenbacher A, Mueller E, Multhoff G, Botzler C, Wiesnet M, Issels R.
    Anticancer Drugs; 1994 Aug 01; 5(4):403-9. PubMed ID: 7949243
    [Abstract] [Full Text] [Related]

  • 16. Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide.
    Kuśnierczyk H, Konarski L, Kowalski P, Radzikowski C.
    Arch Immunol Ther Exp (Warsz); 1997 Aug 01; 45(1):79-85. PubMed ID: 9090445
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of mesna and dimesna after simultaneous intravenous bolus and infusion administration in patients undergoing bone marrow transplantation.
    el-Yazigi A, Ernst P, al-Rawithi S, Legayada E, Raines DA.
    J Clin Pharmacol; 1997 Jul 01; 37(7):618-24. PubMed ID: 9243355
    [Abstract] [Full Text] [Related]

  • 18. Attenuation of cytogenetic damage by 2-mercaptoethanesulfonate in cultured human lymphocytes exposed to cyclophosphamide and its reactive metabolites.
    Wilmer JL, Erexson GL, Kligerman AD.
    Cancer Res; 1986 Jan 01; 46(1):203-10. PubMed ID: 3079586
    [Abstract] [Full Text] [Related]

  • 19. Chemoprotectants for cancer chemotherapy.
    Dorr RT.
    Semin Oncol; 1991 Feb 01; 18(1 Suppl 2):48-58. PubMed ID: 1899489
    [Abstract] [Full Text] [Related]

  • 20. Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells.
    Patzer L, Hernando N, Ziegler U, Beck-Schimmer B, Biber J, Murer H.
    Kidney Int; 2006 Nov 01; 70(10):1725-34. PubMed ID: 17003823
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.